IL141965A0 - Non-endogenous, constitutively activated human g protein-coupled receptors - Google Patents

Non-endogenous, constitutively activated human g protein-coupled receptors

Info

Publication number
IL141965A0
IL141965A0 IL14196599A IL14196599A IL141965A0 IL 141965 A0 IL141965 A0 IL 141965A0 IL 14196599 A IL14196599 A IL 14196599A IL 14196599 A IL14196599 A IL 14196599A IL 141965 A0 IL141965 A0 IL 141965A0
Authority
IL
Israel
Prior art keywords
endogenous
sub
sup
codon
gpcr
Prior art date
Application number
IL14196599A
Other languages
English (en)
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL141965A0 publication Critical patent/IL141965A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
IL14196599A 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors IL141965A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/170,496 US6555339B1 (en) 1997-04-14 1998-10-13 Non-endogenous, constitutively activated human protein-coupled receptors
PCT/US1999/023938 WO2000022129A1 (en) 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors

Publications (1)

Publication Number Publication Date
IL141965A0 true IL141965A0 (en) 2002-03-10

Family

ID=22620080

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14196599A IL141965A0 (en) 1998-10-13 1999-10-12 Non-endogenous, constitutively activated human g protein-coupled receptors
IL141965A IL141965A (en) 1998-10-13 2001-03-12 Non-internally activated human G protein-coupled receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141965A IL141965A (en) 1998-10-13 2001-03-12 Non-internally activated human G protein-coupled receptors

Country Status (15)

Country Link
US (2) US6555339B1 (de)
EP (1) EP1121431B9 (de)
JP (2) JP4685241B2 (de)
KR (1) KR100598752B1 (de)
CN (1) CN1329511C (de)
AT (1) ATE318311T1 (de)
AU (5) AU769987B2 (de)
CA (1) CA2342314A1 (de)
DE (3) DE1121431T1 (de)
DK (1) DK1121431T5 (de)
ES (1) ES2163384T3 (de)
HK (1) HK1038040A1 (de)
IL (2) IL141965A0 (de)
NZ (1) NZ510331A (de)
WO (2) WO2000022129A1 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
ES2289610T3 (es) * 1998-11-20 2008-02-01 Arena Pharmaceuticals, Inc. Receptor acoplado a proteina g humano huerfano rup3.
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
GB9903767D0 (en) * 1999-02-18 1999-04-14 Univ Glasgow Receptor assay
AU6385200A (en) * 1999-07-30 2001-02-19 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for prognostication, diagnosis, prevention, and treatment of bone-related disorders and other disorders
JP4768946B2 (ja) * 1999-11-17 2011-09-07 アリーナ ファーマシューティカルズ， インコーポレイテッド ヒトｇタンパク質共役型受容体の内因性および非内因性型
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
AU2194201A (en) * 1999-12-17 2001-06-25 Astrazeneca Ab Novel compound
WO2001061359A2 (en) * 2000-02-18 2001-08-23 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
GB0003898D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
GB0003902D0 (en) * 2000-02-18 2000-04-05 Glaxo Group Ltd Assay
AU2001241778A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1149907A1 (de) * 2000-04-26 2001-10-31 Aventis Pharma Deutschland GmbH EDG8 Rezeptor, dessen Herstellung und Verwendung
ATE364697T1 (de) * 2000-04-26 2007-07-15 Sanofi Aventis Deutschland Edg8-rezeptor, dessen herstellung und verwendung
AU2001250536A1 (en) * 2000-05-03 2001-11-12 Astrazeneca Ab Methods
WO2001096567A1 (fr) * 2000-06-15 2001-12-20 Takeda Chemical Industries, Ltd. Nouvelle proteine receptrice couplee a la proteine g et adn de ce recepteur
EP1297130A2 (de) * 2000-06-16 2003-04-02 Incyte Genomics, Inc. G-protein gekoppelter rezeptor
EP1293567B1 (de) 2000-06-21 2009-07-29 Takeda Pharmaceutical Company Limited Gpr8 ligand und dafuer kodierende dna
US20040086940A1 (en) * 2000-07-04 2004-05-06 Sachio Shibata Novel g protein-coupled receptor protein and dna thereof
AU2002212140A1 (en) * 2000-08-18 2002-02-25 Novartis Ag Inflammation related g-protein coupled receptor
US7462457B2 (en) * 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
WO2001027632A2 (en) * 2000-10-02 2001-04-19 Biofocus Discovery Limited Cellular receptor mutations predicted by multiple-sequence-allignment
WO2002044368A1 (fr) * 2000-11-30 2002-06-06 Takeda Chemical Industries, Ltd. Nouvelles proteines du recepteur couple a la proteine g et leurs adn
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US7241579B2 (en) 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
CN1516706A (zh) * 2001-02-26 2004-07-28 阿伦纳药品公司 人g蛋白偶联受体的内源性和非内源性形式
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US6919176B2 (en) * 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
US7247440B2 (en) 2001-05-15 2007-07-24 Takeda Pharmaceutical Company Limited Method of screening preventives or remedies for obesity
US20020177190A1 (en) * 2001-05-24 2002-11-28 Yanbin Liang Recombinant simian GPR3 receptor
EP1404708A4 (de) * 2001-06-05 2005-01-19 Arena Pharm Inc Nichtendogene, konstitutiv aktivierte versionen des g-protein-gekoppelten rezeptors gcr1 aus pflanzen
JP2003018992A (ja) * 2001-06-28 2003-01-21 Inst Of Physical & Chemical Res Ｐａｅｌ受容体、Ｐａｅｌ受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法
WO2003006504A2 (en) * 2001-07-13 2003-01-23 Akzo Nobel N.V. Allelic variants of gpr50
US20030109044A1 (en) * 2001-10-16 2003-06-12 Millennium Pharmaceuticals, Inc. Methods of using 279, a human G protein-coupled protein receptor
US20030119742A1 (en) * 2001-11-05 2003-06-26 Millennium Pharmaceuticals, Inc. Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804
US6902902B2 (en) 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
JP4360915B2 (ja) 2002-01-07 2009-11-11 ユーロスクリーン・ソシエテ・アノニム Ｇタンパク質共役受容体ｇｐｒ４３のリガンドおよびその使用
EP1336655A1 (de) * 2002-01-12 2003-08-20 Aventis Pharma Deutschland GmbH Verfahren zur Identifikation von konstitutiv aktiven Mutanten
AU2003210644A1 (en) * 2002-01-23 2003-09-02 Arena Pharmaceuticals, Inc. Non-endogenous versions of human g protein-coupled receptor: fshr
WO2003066077A2 (en) * 2002-02-06 2003-08-14 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
DE60332320D1 (de) 2002-02-14 2010-06-10 Takeda Pharmaceutical Neues screening-verfahren
AU2003218234A1 (en) * 2002-03-15 2003-09-29 Arena Pharmaceuticals, Inc. Methods of expressing non-endogenous g protein coupled receptors in cells
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003241037A1 (en) * 2002-06-08 2003-12-22 Astrazeneca Ab Methods for the detection of polymorphisms in human gpr50
CN100473662C (zh) * 2002-08-01 2009-04-01 阿瑞那制药公司 治疗缺血性心脏病及充血性心衰竭的人类g蛋白偶联受体及其调节物
WO2004015426A1 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human cxc chemokine receptor 5(cxcr5)
WO2004015427A2 (en) * 2002-08-06 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2004017994A1 (ja) * 2002-08-22 2004-03-04 Kyowa Hakko Kogyo Co., Ltd. 喘息の予防および／または治療剤
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
PL376659A1 (pl) 2002-11-06 2006-01-09 Tularik Inc. Skondensowane związki heterocykliczne
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
AU2003297644A1 (en) * 2002-12-04 2004-06-23 Synaptic Pharmaceutical Corporation Uses of the snorf55 receptor
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
EP1603585A2 (de) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotid kodierend für eine neue humane g-proteingekoppelte rezeptor-variante von hm74, hgprbmy74
US7427487B2 (en) * 2003-03-18 2008-09-23 Arena Pharmaceuticals, Inc. Constitutively active CXCR3 G protein-coupled chemokine receptor and modulators thereof for the treatment of inflammatory disorders
WO2004093912A1 (ja) * 2003-04-23 2004-11-04 Kyowa Hakko Kogyo Co. Ltd. 好中球性炎症疾患の予防および／または治療剤
WO2004099419A2 (en) * 2003-04-30 2004-11-18 Arena Pharmaceuticals, Inc. Methods and compositions for identifying modulators of g protein-coupled receptors
CN1809587B (zh) * 2003-05-20 2010-11-10 格拉斯哥大学管理处 涉及g-蛋白偶联受体寡聚体的材料和方法
WO2005026728A1 (ja) * 2003-09-11 2005-03-24 Takeda Pharmaceutical Company Limited スクリーニング方法
EP1677778A2 (de) * 2003-10-09 2006-07-12 Inverseon, Inc. Verfahren zur behandlung von atemwegserkrnakungen mit betaadrenergen inversen agonisten
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
WO2005040829A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040211A2 (en) * 2003-10-23 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005040828A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005040825A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
DE602004011400T2 (de) * 2004-01-29 2009-01-22 Cellzome Ag Behandlung von neurodegenerativen krankheiten mit gpr49
ME00059B (me) 2004-02-20 2010-06-10 Oksidekahidronaftalen modulatori hm74
WO2005101005A1 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 32 (gpr32)
EP1741792B1 (de) * 2004-04-27 2010-11-03 Takeda Pharmaceutical Company Limited Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
NZ580115A (en) 2004-09-23 2010-10-29 Genentech Inc Cysteine engineered antibody light chains and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
GB0508988D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
US8429755B2 (en) 2005-05-26 2013-04-23 Sandisk Technologies Inc. System and method for receiving digital content
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JP2009511063A (ja) * 2005-10-14 2009-03-19 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｇｐｒ２２およびそれに関連する方法
CA2627877A1 (en) 2005-11-10 2007-05-24 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto
ATE544854T1 (de) * 2007-03-22 2012-02-15 Heptares Therapeutics Ltd Mutante g-protein-gekoppelte rezeptoren und selektionsverfahren dafür
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
EP2146210A1 (de) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
WO2010091692A2 (en) * 2009-04-30 2010-08-19 H. Lundbeck A/S Constitutively active mutants and uses thereof
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
CN114246952A (zh) 2010-06-08 2022-03-29 基因泰克公司 半胱氨酸改造的抗体和偶联物
JP5804341B2 (ja) * 2010-08-06 2015-11-04 国立大学法人山口大学 エストロゲン関連疾患の判定方法
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
JP6270859B2 (ja) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ ピロロベンゾジアゼピン−抗体結合体
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
PT2906296T (pt) 2012-10-12 2018-06-01 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
RS53818B1 (en) 2012-10-12 2015-06-30 Spirogen Sàrl PIROLOBENZODIAZEPINI I NJIHOVI conjugated
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
KR101995621B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항-cd22 항체 컨주게이트
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
EA201690278A1 (ru) 2013-07-25 2016-06-30 Новартис Аг Циклические полипептиды для лечения сердечной недостаточности
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
KR20160042080A (ko) 2013-08-12 2016-04-18 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054983B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2016007826A (es) 2013-12-16 2017-03-31 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco.
JP6671292B2 (ja) 2013-12-16 2020-03-25 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
EP3134433A4 (de) 2014-04-25 2017-10-04 Libramen Naturals Inc. G-protein-gekoppelte rezeptor-22-transformierte zelllinien und verwendungen dafür
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (de) 2014-09-12 2019-11-20 Genentech, Inc. Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
EP3223854A1 (de) 2014-11-25 2017-10-04 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20200164068A1 (en) 2016-02-16 2020-05-28 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
EP3416641A1 (de) 2016-02-16 2018-12-26 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulatoren von ccr9 zur behandlung von tumorresistenz gegenüber immunreaktionen
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
CN110536703A (zh) 2017-04-20 2019-12-03 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
RU2020113749A (ru) 2017-09-20 2021-10-20 пиЭйч ФАРМА Ко., ЛТД. Аналоги таиланстатина
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR102653878B1 (ko) 2018-08-01 2024-04-01 난트퀘스트, 인크. 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 (a quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies)
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114848822A (zh) * 2022-06-01 2022-08-05 合肥工业大学 Gpr31抑制剂在制备预防和治疗血管钙化药物中的应用
WO2024044659A1 (en) * 2022-08-24 2024-02-29 Tectonic Therapeutic, Inc. Constitutively active g protein-coupled receptor compositions and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180529T3 (es) 1990-02-26 2003-02-16 Univ Leland Stanford Junior Identificacion y expresion de secuencias de adn de un receptor de esteroides de insectos.
AU655850B2 (en) 1991-10-01 1995-01-12 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A method of identifying ligands and antagonists of ligands
ATE365209T1 (de) * 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US5861309A (en) 1992-09-25 1999-01-19 Synaptic Pharmaceutical Corporation DNA endoding human alpha 1 adrenergic receptors
EP0612845A3 (en) 1993-02-26 1994-09-21 American Cyanamid Co Purified opioid receptor.
WO1995013373A1 (en) 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
EP0743520A3 (de) * 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Neue Verwendungen von Gal4-Rezeptor-Konstruktionen
US5573944A (en) 1994-07-22 1996-11-12 President And Fellows Of Harvard College Yeast cell expressing heterologous receptor kinase
WO1996005302A1 (en) 1994-08-11 1996-02-22 Takeda Chemical Industries, Ltd. G protein coupled receptor protein, production, and use thereof
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
CN1147505C (zh) * 1995-06-06 2004-04-28 人体基因组科学有限公司 G蛋白受体htnad29
WO1997011159A1 (en) 1995-09-20 1997-03-27 Molecular Geriatrics Corporation Yeast receptor and g-protein fusion protein
FR2742033B1 (fr) * 1995-12-08 1998-01-16 Achart Jacques Appareil pour l'ouverture de coquillages de mollusques bivalves
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5932779A (en) * 1996-06-10 1999-08-03 Millennium Pharmaceuticals, Inc. Screening methods for compounds useful in the regulation of body weight
WO1998000552A2 (en) 1996-07-02 1998-01-08 President And Fellows Of Harvard College Receptor tyrosine phosphatase, and uses related thereto
EP0929691B1 (de) * 1996-09-24 2004-12-15 Cadus Pharmaceutical Corporation Verfahren und zusammensetzungen für die identifizierung von receptor effectoren
WO1998029439A1 (en) 1996-12-27 1998-07-09 Merck & Co., Inc. Galanin receptor galr2 and nucleotides encoding same
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
WO1998038217A1 (en) 1997-02-27 1998-09-03 Milt Teitler Constitutively activated serotonin receptors
ATE423313T1 (de) 1997-04-14 2009-03-15 Arena Pharm Inc Methode zum identifizieren von modulatoren der zelloberflächenmembranrezeptoren,nützlich zur behandlung von krankheiten
US6555339B1 (en) * 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
US5891720A (en) 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
EP0878542A3 (de) 1997-04-22 2000-04-19 Smithkline Beecham Corporation CDNS Klon HMTMF81 der für einen neuen menschlichen 7-Transmembranrezeptor kodiert
AU7966098A (en) 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
US5955308A (en) 1997-06-18 1999-09-21 Smithkline Beecham Corporation cDNA clone HEAOD54 that encodes a human 7-transmembrane receptor
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
JP4280886B2 (ja) 1997-11-11 2009-06-17 小野薬品工業株式会社 ヒトリゾホスファチジン酸受容体物質およびその用途
SE9704836D0 (sv) 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
DE69941330D1 (de) 1998-03-26 2009-10-08 Univ R Neue g-protein-gekoppelte rezeptoren aus säugetieren mit extrazellulären leucin-reicher region
AU764766B2 (en) 1998-04-14 2003-08-28 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
DE69940923D1 (de) * 1998-07-31 2009-07-09 Arena Pharm Inc Endogene, konstitutiv aktivierte g-protein gekoppelte waisenrezeptoren
EP1111049A4 (de) 1998-09-03 2002-10-29 Asahi Chemical Ind Neues Rezeptorprotein und Verfahren zur Diagnose von Entzündungskrankheiten unter dessen Verwendung
US20030229216A1 (en) * 1998-10-13 2003-12-11 Ruoping Chen Constitutively activated human G protein coupled receptors
CA2348688A1 (en) 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human g protein-coupled receptors
CN1341123A (zh) 1999-02-19 2002-03-20 武田药品工业株式会社 新型g蛋白偶联型受体蛋白及其dna
CA2379360A1 (en) 1999-07-15 2001-02-08 Solvay Pharmaceuticals B.V. Human g-protein coupled receptor
WO2001007606A1 (en) 1999-07-27 2001-02-01 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2003510027A (ja) 1999-08-17 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Ｐｇｐｃｒ−３ポリペプチドおよびそのｄｎａ配列
WO2001014577A1 (en) 1999-08-24 2001-03-01 Smithkline Beecham Corporation Molecular cloning of a galanin like 7tm receptor (axor40)
WO2001016159A1 (en) 1999-08-27 2001-03-08 Smithkline Beecham Corporation Gpcr, theant
GB9923889D0 (en) 1999-10-08 1999-12-08 Pfizer Ltd Novel polypeptide
GB9924951D0 (en) 1999-10-21 1999-12-22 Pfizer Ltd Novel polypeptide
AU1575601A (en) 1999-10-27 2001-05-08 Pharmacia & Upjohn Company G protein-coupled receptors expressed in brain
WO2001036471A2 (en) 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
WO2000021987A9 (en) 2000-08-24
KR100598752B1 (ko) 2006-07-11
AU2008200231A1 (en) 2008-02-07
DE69929993D1 (de) 2006-04-27
AU2011200016A1 (en) 2011-01-27
AU6430799A (en) 2000-05-01
US7410777B2 (en) 2008-08-12
CA2342314A1 (en) 2000-04-20
JP2002527727A (ja) 2002-08-27
WO2000021987A2 (en) 2000-04-20
WO2000022129A1 (en) 2000-04-20
DE1121431T1 (de) 2002-05-23
EP1121431B9 (de) 2007-10-24
CN1329511C (zh) 2007-08-01
DE69929993T4 (de) 2008-08-28
DK1121431T3 (da) 2006-06-26
AU2004203102B2 (en) 2007-10-18
AU2004203102A1 (en) 2004-07-29
WO2000021987A3 (en) 2000-07-13
NZ510331A (en) 2004-07-30
JP4672866B2 (ja) 2011-04-20
ATE318311T1 (de) 2006-03-15
HK1038040A1 (en) 2002-03-01
US20030105292A1 (en) 2003-06-05
DE69929993T2 (de) 2006-10-26
AU769987B2 (en) 2004-02-12
ES2163384T1 (es) 2002-02-01
ES2163384T3 (es) 2006-12-01
WO2000022129A9 (en) 2000-09-14
KR20010085911A (ko) 2001-09-07
IL141965A (en) 2008-08-07
AU2011200511A1 (en) 2011-03-03
DK1121431T5 (da) 2008-03-03
JP2003531565A (ja) 2003-10-28
EP1121431B1 (de) 2006-02-22
JP4685241B2 (ja) 2011-05-18
CN1398298A (zh) 2003-02-19
US6555339B1 (en) 2003-04-29
EP1121431A1 (de) 2001-08-08

Similar Documents

Publication Publication Date Title
HK1038040A1 (en) Non-endogenous, constitutively activated human g protein-coupled receptors
ES2243095T3 (es) Receptores acoplados a proteina g humanos huerfanos.
Jüppner et al. The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
Howard et al. Molecular cloning and characterization of a new receptor for galanin
Baud et al. EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments
US5883075A (en) Cyclic endothelin antagonists
AU1769601A (en) Endogenous and non-endogenous versions of human G protein-coupled receptors
PT1012274E (pt) Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
EP1007563A1 (de) Hm74a rezeptor
Blomenröhr et al. Differences in structure–function relations between nonmammalian and mammalian gonadotropin-releasing hormone receptors
Unson et al. The role of histidine-1 in glucagon action
ES2201061T3 (es) Genes de receptores opioides delta.
Delporte et al. Discovery of a potent atrial natriuretic peptide antagonist for ANPA receptors in the human neuroblastoma NB-OK-1 cell line
Maiti et al. GnRH-II analogs for selective activation and inhibition of non-mammalian and type-II mammalian GnRH receptors
Mochizuki et al. Cloning and expression of the human 5-HT1B-type receptor gene
CA2330251A1 (en) Cloning and identification of the motilin receptor
DK0692026T3 (da) En human T-cellereceptor fra den G-proteinkoblede receptorfamilie
Koshimizu et al. Truncation of the receptor carboxyl terminus impairs membrane signaling but not ligand binding of human ETB endothelin receptor
Suva et al. Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor
US7816492B2 (en) Human G protein-coupled receptors
Langer et al. Lysine 195 and aspartate 196 in the first extracellular loop of the VPAC1 receptor are essential for high affinity binding of agonists but not of antagonists
Chhajlani Characterization of a putative α-MSH antagonist 153N-6 at melanocortin receptor subtypes by radioligand binding
Brauns et al. Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity
US20050020492A1 (en) Melanin-concentrating hormone analogs
Shibasaki et al. Characterization of the carboxyl terminal‐truncated endothelin B receptor coexpressed with G protein‐coupled receptor kinase 2

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed